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Background: Pulmonary hypertension (PH) is commonly observed in patients with advanced idiopathic pul-
monary fibrosis (IPF). Despite the availability of therapies for both IPF and PH, none are approved for PH
treatment in the context of significant pulmonary disease. This study will investigate the use of sildenafil added
to pirfenidone in patients with advanced IPF and risk of PH, who represent a group with a high unmet medical
need.
Methods: This Phase IIb, randomised, double-blind, placebo-controlled trial is actively enrolling patients and
will study the efficacy, safety and tolerability of sildenafil or placebo in patients with advanced IPF and inter-
mediate or high probability of Group 3 PH who are receiving a stable dose of pirfenidone. Patients with ad-
vanced IPF (diffusing capacity for carbon monoxide ≤40% predicted) and risk of Group 3 PH (defined as mean
pulmonary arterial pressure ≥20mm Hg with pulmonary arterial wedge pressure ≤15mm Hg on a previous
right-heart catheterisation [RHC], or intermediate/high probability of Group 3 PH as defined by the 2015
European Society of Cardiology/European Respiratory Society guidelines) are eligible. In the absence of a
previous RHC, patients with an echocardiogram showing a peak tricuspid valve regurgitation velocity≥2.9 m/s
can enrol if all other criteria are met. The primary efficacy endpoint is the proportion of patients with disease
progression over a 52-week treatment period. Safety will be evaluated descriptively.
Discussion: Combination treatment with sildenafil and pirfenidone may warrant investigation of the treatment of
patients with advanced IPF and pulmonary vascular involvement leading to PH.
1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive and
often rapidly fatal fibrosing interstitial lung disease with a 5-year sur-
vival rate between 20% and 40% [1,2], which is lower than that re-
ported for many common cancers [2,3]. IPF profoundly affects patients'
quality of life (QoL), with dyspnoea reducing physical functioning,
leading to limited independence and depression [4,5]. Pirfenidone is an
oral antifibrotic agent that slows IPF disease progression and, along
with nintedanib, is one of only two antifibrotic therapies that were
conditionally recommended for the treatment of IPF in the 2015 update
to the American Thoracic Society/European Respiratory Society/Japa-
nese Respiratory Society/Latin American Thoracic Society IPF treat-
ment guidelines [6]. In addition, pirfenidone significantly reduces the
decline in 6-minute walk distance (6MWD), which is a measure of an
individual's functional status and ability to undertake activities of daily
living [7,8], and significantly reduces the risk of death from any cause
up to 120 weeks [9].
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Pulmonary hypertension (PH) is often found in patients with ad-
vanced IPF, and its occurrence increases with IPF disease severity. The
incidence and prevalence of PH in patients with IPF remain unclear and
estimates vary widely, from 8.1% to 84%, reflecting the heterogeneous
subpopulations of patients studied, underlying disease severity, disease
definition and different diagnostic measures used [10–14]. PH is a
malignant prognostic determinant in patients with IPF, associated with
a three-fold increase in mortality, especially when systolic pulmonary
arterial pressure (sPAP) by echocardiogram (ECHO) exceeds 50mm Hg
[11,15,16]. The development of PH in patients with underlying IPF is
also associated with a diminished exercise tolerance and QoL.
Although several targeted treatments are available for Group 1
(pulmonary arterial hypertension [PAH]) and Group 4 (chronic
thromboembolic PH and other pulmonary artery obstructions [Table 1]
[17]) PH, there are currently no approved therapies for PH in the
context of significant pulmonary disease (Group 3), including PH in the
context of IPF [17]. Indeed, therapies approved to treat PH have not
been effective at targeting the underlying fibrotic parenchymal changes
that occur in IPF [18–21], and the use of PH drugs in patients with IPF
is not supported by evidence from randomised clinical trials.
Previous studies investigating the use of PAH drugs, including bo-
sentan, ambrisentan, macitentan and riociguat, in patients with IPF
have yielded inconsistent results, which may be due to differences in
patient populations and experimental design [18–22]. Additionally,
Phase II and III clinical trials in IPF, including the pirfenidone trials
[23,24], have generally excluded patients with advanced IPF and/or
PH. Nevertheless, it is unlikely that approved antifibrotics would have a
notable effect on the vascular abnormalities that occur in patients with
interstitial lung disease. Therefore, patients with PH in the context of
IPF represent a group with a high unmet medical need.
Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor that stabilises
cyclic guanine monophosphate (cGMP), the secondary messenger for
the pulmonary vasodilator nitric oxide (NO), and is approved for the
treatment of PAH [25], but not PH in the context of significant pul-
monary disease. In addition, sildenafil may confer survival benefits in
paediatric patients with PAH [26,27] and improve haemodynamics in
patients with thalassemia at risk of PH [28].
Results of previous clinical trials of sildenafil in PH in the context of
IPF have generally been inconclusive, possibly owing to their small
sample sizes, short observation periods, imprecise definitions of study
populations or primary endpoint selection [29–34]. In the STEP-IPF
trial, sildenafil was studied in a cohort of 180 patients with advanced
IPF (defined as diffusing capacity for carbon monoxide [DLCO]< 35%
predicted) who were expected to have a high prevalence of PH. Al-
though the primary endpoint of≥20% improvement in 6MWD was not
met, effects on secondary endpoints, such as DLCO, dyspnoea, oxyhae-
moglobin saturation (SaO2) and QoL, achieved statistical significance
[32]. In a substudy of STEP-IPF, patients with right ventricular systolic
dysfunction experienced a significant 99-m lesser decline in 6MWD and
improved QoL when treated with sildenafil compared with placebo
[33]. Importantly, previous clinical trials of sildenafil in patients with
IPF have not revealed any safety signals [32].
The beneficial effects of sildenafil on oxygenation and QoL para-
meters render it an attractive therapy for use in patients with IPF,
particularly in the context of background antifibrotic therapy. Indeed,
evidence from a small case-control study of 17 patients with progressive
IPF suggested that sildenafil and pirfenidone may be administered
safely in combination and may be associated with preserved DLCO,
setting a precedent for further controlled clinical trials investigating
combination treatment with these two drugs [35].
The present study will evaluate the efficacy, safety and tolerability
of sildenafil or placebo added to pirfenidone in patients with advanced
IPF and intermediate or high probability of Group 3 PH who are re-
ceiving a stable dose of pirfenidone with demonstrated tolerability.
2. Materials and methods
2.1. Study design
This Phase IIb, randomised, placebo-controlled, multicentre, inter-
national study will investigate the efficacy, safety and tolerability of
sildenafil or placebo in patients with advanced IPF and intermediate or
high probability of Group 3 PH who are receiving pirfenidone
(1602–2403mg/day) with demonstrated tolerability. For this, patients
should have received pirfenidone for at least 12 weeks, with no inter-
ruption or significant adverse events (AEs) due to pirfenidone in the last
28 days prior to screening.
The study will consist of five phases (Fig. 1; Table 2). First, a run-in
period of 12 weeks will be provided for countries where patients will
not otherwise be able to receive pirfenidone due to reimbursement
restrictions. Second, a screening period of up to 28 days will be pre-
ceded by a 28-day washout period in patients receiving a prohibited
medication; patients not receiving a prohibited medication will directly
enter screening. In the 4 weeks prior to the screening visit, patients
must not have experienced a new or ongoing AE of Grade 2 [36] or
higher that is considered by the investigator to be related to pirfeni-
done, or have a>7-day interruption of pirfenidone for any reason.
Third, a 52-week, double-blind treatment period, including 10 visits,
will form the main part of the study. After the treatment period, pa-
tients will continue to receive pirfenidone during the fourth phase, a
safety follow-up of 4 weeks. During the fifth phase, an additional 12-
month safety period after study visit 10, patients will be offered the
possibility of continued access to pirfenidone, with evaluation ap-
proximately every 3 months. Patients will not continue to receive sil-
denafil after the 52-week, double-blind treatment period.
Patients who meet all eligibility criteria and provide written, in-
formed consent will be randomised 1:1 by an interactive web-based
response system to receive either oral pirfenidone plus oral sildenafil or
oral pirfenidone plus matched placebo. Randomisation will be stratified
by the availability of a previous right-heart catheterisation ([RHC] yes/
no) and by a forced expiratory volume in 1 s (FEV1)/forced vital ca-
pacity (FVC) ratio (below/above 0.8) to ensure an equal distribution of
patients with some degree of pulmonary obstruction in both treatment
groups. Pirfenidone will be administered three times daily, at the same
times each day, and is expected to remain within the dose range of 1602
to 2403mg/day throughout the study. Patients will also receive silde-
nafil 20mg, or matched placebo, three times daily, in accordance with
the approved dose for PAH; treatment with sildenafil will be monitored
by a physician experienced in the treatment of PH. Daily dosing ad-
herence for study medication will be recorded in the patient diary.
2.2. Patient population
At screening, patients will be aged 40 to 80 years, have a diagnosis
of IPF for at least 3 months that is confirmed by the investigator and in
line with the 2011 International Consensus Guidelines (2011) [37], be
of World Health Organization functional class II or III and have a
6MWD of 100 to 450m (Table 3). For this study, patients must present
with advanced IPF defined by a measurable DLCO≤40% predicted at
screening AND risk of Group 3 PH, defined as mean pulmonary arterial
pressure (mPAP) ≥20mm Hg with pulmonary artery wedge pressure
≤15mm Hg on a previous RHC OR intermediate/high probability of
Group 3 PH as defined by the 2015 European Society of Cardiology
(ESC)/ERS guidelines (Fig. 2) [17]. In the absence of a previous RHC,
patients with an ECHO showing a peak tricuspid valve regurgitation
velocity (TRV)≥2.9m/s will be considered eligible, assuming all other
criteria are met. A DLCO of≤40% predicted at screening was selected to
define advanced IPF based on evidence that this threshold is associated
with an increased risk of mortality [37], provide overlap with previous
pirfenidone clinical studies and, when combined with RHC/ECHO in-
clusion criterion, increase the likelihood of including patients with
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pulmonary vasculopathy and a risk of PH. An mPAP ≥20mm Hg was
selected as an inclusion criterion as there is evidence that borderline PH
is associated with increased mortality [33,38].
Patients with a history of PH that is not in the context of significant
pulmonary disease (Group 3 [Table 1]) will be excluded from the study.
Other exclusion criteria include a history of clinically significant cardiac
and/or pulmonary disease (other than IPF or Group 3 PH), hypotension,
FEV1/FVC ratio<0.70 post-bronchodilator, extent of emphysema greater
than the extent of fibrotic changes (honeycombing and reticular changes)
on any previous high-resolution computed tomography scan in the opinion
of the investigator or history of drug and toxin use known to cause PAH. In
addition, patients will be excluded if they meet the exclusion criteria based
on pirfenidone and sildenafil reference safety information. Key inclusion
and exclusion criteria are provided in Table 3.
Low steroid doses (15mg prednisolone or equivalent) and N-acet-
ylcysteine are permitted throughout the study period. In addition,
corticosteroids may be used at the discretion of the investigator,
without dose restriction, for up to 28 days in patients experiencing an
acute exacerbation. During the study period, the use of the following
drugs is prohibited: cytotoxic, immunosuppressive, cytokine-mod-
ulating or receptor-antagonist agents; the strong cytochrome (CYP) 1A2
inhibitors fluvoxamine and enoxacin; P-glycoprotein inhibitors or in-
ducers; any medications used specifically for the treatment of IPF or PH
(other than the study drugs), including but not limited to endothelin
(ET) receptor antagonists, prostaglandins, guanylyl cyclase stimulators
such as riociguat and other PDE-5 inhibitors; and NO donors.
Fig. 1. Study design schematic.
ICF informed consent form.
* A prior run-in period will be provided for countries where
patients will not be able to receive pirfenidone for 12 weeks
due to reimbursement issues. The run-in period can include
the washout period (if applicable).
† Patients will be required to discontinue all prohibited
medications and undergo a 28-day washout period prior to
entering the study. Patients not taking a prohibited medi-
cation will directly enter screening.
‡ After the completion of the treatment period (visit 10),
patients will be offered the possibility of receiving pirfeni-
done within the study protocol for up to 12 months' safety
follow-up.
Table 2
Summary of study phases.
Phase Duration
Run-in period (if
needed)
12 weeks (for patients who will not otherwise be able to
receive pirfenidone due to reimbursement restrictions)
Screening period ± 28-day washout period
Screening period (up to 28 days); evaluation of patients
based on inclusion and exclusion criteria
Double-blind
treatment period
52 weeks, 10 visits (1:1 pirfenidone plus oral sildenafil or
oral pirfenidone plus matched placebo)
Follow-up period 4 weeks (continue to receive pirfenidone)
Safety follow-up 12 months from visit 10 (continue to receive pirfenidone)
Table 1
Clinical classification of pulmonary hypertension (adapted from Ref. [17]).
Group 1: Pulmonary arterial hypertension Group 3: Pulmonary hypertension due to lung diseases and/or hypoxia
1.1 Idiopathic
1.2 Heritable
1.2.1 BMPR2 mutation
1.2.2 Other mutations
1.3 Drugs and toxins induced
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental lung diseases
Group 1: Pulmonary veno-occlusive disease and/or pulmonary
capillary haemangiomatosis
Group 4: Chronic thromboembolic pulmonary hypertension and other pulmonary artery
obstructions
1.1 Idiopathic
1.2 Heritable
1.2.1 EIF2AK4 mutation
1.2.2 Other mutations
1.3 Drugs, toxins and radiation induced
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
4.1 Chronic thromboembolic pulmonary hypertension
4.2 Other pulmonary artery obstructions
4.2.1 Angiosarcoma
4.2.2 Other intravascular tumours
4.2.3 Arteritis
4.2.4 Congenital pulmonary artery stenosis
4.2.5 Parasites (hydatidosis)
Group 1: Persistent pulmonary hypertension of the newborn Group 5: Pulmonary hypertension with unclear and/or multifactorial mechanisms
Group 2: Pulmonary hypertension due to left heart disease 5.1 Haematologic disorders: chronic haemolytic anaemia, myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis,
neurofibromatosis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4 Others: pulmonary tumoural thrombotic microangiopathy, fibrosing mediastinitis, chronic renal
failure (with/without dialysis), segmental pulmonary hypertension
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract
obstruction and congenital cardiomyopathies
2.5 Congenital/acquired pulmonary vein stenosis
BMPR2 bone morphogenetic protein receptor type 2; EIF2AK4 eukaryotic translation initiation factor 2 alpha kinase 4; HIV human immunodeficiency virus.
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2.3. Study objectives
This study will evaluate the efficacy, safety and tolerability of sil-
denafil compared with placebo when added to pirfenidone in the study
population. The primary efficacy endpoint will be the proportion of
patients showing disease progression over a 52-week treatment period,
as evidenced by reaching the composite endpoint of relative decline in
6MWD of ≥15% from baseline, respiratory-related non-elective hos-
pitalisations or all-cause mortality. A relative decline in 6MWD from
baseline is further specified as any decline> 25% from baseline, or a
decline between 15% and 25% from baseline if accompanied by at least
one of the following: worsening of SpO2 desaturation during the 6-
minute walk test (6MWT) compared with baseline; worsening of the
maximum Borg scale during the 6MWT compared with baseline; and
increased O2 requirements during the 6MWT compared with baseline.
The composite primary endpoint has been expanded from the primary
endpoint of the 6MWT used previously in this patient population and in
clinical trials of PAH [30–32,39]. The 15% to 25% decline in the 6MWT
utilised secondary criteria to avoid having patients return to the site to
do a repeat 6MWD as occurred in the Phase III studies of pirfenidone to
confirm a>10% absolute change in % predicted FVC or 50-m decline
in 6MWD.
The secondary efficacy objective for this study will further evaluate
the efficacy of adding sildenafil compared with placebo to pirfenidone
on each of the individual components of the primary endpoint, as well
as other parameters, as described in Table 4. The safety objective for
this study will be to evaluate the safety of adding sildenafil compared
with placebo to pirfenidone, and will be assessed by the nature, fre-
quency, severity, relationship and timing of treatment-emergent AEs,
changes in vital signs, findings on physical examination, 12-lead elec-
trocardiogram (ECG) and study drug discontinuation (Table 4).
2.4. Safety considerations
Due to the potential risk of developing photosensitivity reaction/
rash with pirfenidone, patients will be advised to avoid/minimise
Table 3
Key inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
•Diagnosis of IPF for ≥3 months prior to screening
•Investigator-confirmed IPF at screening consistent with the 2011 guidelines [37]
•Advanced IPF, as defined as measurable DLCO≥40% predicted
•Intermediate or high probability of Group 3 PH
•Received pirfenidone for≥12weeks at 1602–2403mg/day≥4 weeks prior to screening,
without any new or ongoing Grade 2 or higher adverse events (NCI CTCAE version 4.03)
considered by the investigator as related to pirfenidone, or an interruption of pirfenidone
for> 7 days for any reason
•WHO functional class II or III [37,56]
•6MWD 100–450m
•For women of childbearing potential and for men who are not surgically sterile,
agreement to remain abstinent or to use contraception measures
•History of PH other than Group 3 PH due to interstitial lung disease
•History of clinically significant cardiac and/or pulmonary disease (other than
IPF or Group 3 PH)
•History of drug or toxin use known to cause PAH, including aminorex,
fenfluramine, dexfenfluramine and amphetamines
•FEV1/FVC ratio<0.70 post-bronchodilator
•SpO2 at rest< 92% with ≥6 L supplemental oxygen
•Extent of emphysema greater than extent of fibrotic changes on any previous
HRCT scan, in the opinion of the investigator
•Smoking tobacco in the previous 3 months, or illicit drug or significant alcohol
abuse
•ECG with heart rate–corrected QT interval (corrected to Fridericia's formula)
≥500 ms at screening, or family or personal history of long QT syndrome
•Exclusion criteria based on pirfenidone or sildenafil reference safety
information
6MWD 6-minute walk distance; DLCO diffusing capacity for carbon monoxide; ECG electrocardiogram; FEV1 forced expiratory volume in 1 s; FVC forced vital capacity; HRCT high-
resolution computed tomography; IPF idiopathic pulmonary fibrosis; NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events; PAH pulmonary arterial
hypertension; PH pulmonary hypertension; SpO2 oxyhaemoglobin saturation; WHO World Health Organization.
Fig. 2. Key inclusion (A) and eligibility criteria for risk of Group
3 PH (B).
DLCO diffusing capacity for carbon monoxide; ECHO echocardio-
gram; ERS European Respiratory Society; ESC European Society of
Cardiology; IPF idiopathic pulmonary fibrosis; mPAP mean pul-
monary arterial pressure; PAWP pulmonary artery wedge pressure;
PH pulmonary hypertension; RHC right-heart catheterisation; TRV
tricuspid valve regurgitation velocity. Adapted from Ref. [17].
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exposure to sunlight, wear sunscreen with sun protection factor ≥50
and ultraviolet (UV)-A and UV-B protection and to wear clothing that
protects against the sun. Dose reduction or temporary treatment dis-
continuation may be necessary in some patients with photosensitivity
reaction or rash. Patients will be advised to take pirfenidone with food
to reduce the likelihood of developing gastrointestinal (GI) symptoms,
and dose modifications may be necessary in some patients with GI AEs.
Due to the known mechanism of action of sildenafil, the effect of va-
sodilation on a patient's underlying medical condition should also be
considered.
If clinically significant treatment-emergent AEs or toxicity are ex-
perienced by patients in either treatment group, treatment of symptoms
and/or temporary dose reduction, interruption or discontinuation will
be considered by the investigator. Following a treatment interruption of
more than 14 days, pirfenidone can be retitrated at one capsule three
times a day from Days 1 to 7; two capsules three times a day from Days
8 to 14; and three capsules three times a day from Day 15 onwards.
Liver function tests will be performed at screening and Day 1 prior
to study drug initiation, and at each subsequent clinic visit during the
study. In the event of a significant elevation in liver aminotransferases
(> 3–5×upper limit of normal [ULN]), pirfenidone dose will be ad-
justed or discontinued.
2.5. Statistical methods
There are no reference data available on the use of pirfenidone in
this patient population with a measurable DLCO≤40% predicted and
mPAP ≥20mm Hg on RHC or ECHO of intermediate or high prob-
ability of PH, as defined by the 2015 ESC/ERS guidelines (peak TRV
≥2.9m/s) [17]. Approximately 176 patients are planned to be enrolled
at 75 centres in Canada, Europe (EU), Eastern Europe, the Middle East
and South Africa.
Patients will be randomised 1:1 to the two treatment groups. The
planned sample size is based on the primary endpoint, proportion of
patients with disease progression, and assumes 80% power and a one-
sided significance level of 5%. Given the disease progression rate of
72% in patients with advanced IPF (DLCO< 35%) by 52 weeks in the
CAPACITY (Study 004 and Study 006) and ASCEND (Study 016) trials
[23,24], and assuming an additive effect of sildenafil on pirfenidone, a
disease progression rate of 54% in the combination treatment group is
assumed, and an absolute difference of 18% (relative reduction of 25%)
in disease progression rate is considered a clinically meaningful treat-
ment benefit.
Patient demographics and baseline characteristics, such as sex, age
and race, will be summarised by treatment arm using means or medians
for continuous variables and proportions for categorical variables.
Primary and secondary efficacy analyses will include all randomised
patients, with patients grouped according to their assigned treatment.
Primary analysis of the composite efficacy endpoint will be based upon
the intent-to-treat population, with no imputation for patients who
discontinue treatment prematurely. A sensitivity analysis will repeat
the above analysis in the per-protocol population. Rates of disease
progression in each treatment group will be compared by means of a
Chi-square test with a one-sided significance level of ɑ=0.05. For
secondary efficacy endpoint assessment, progression-free survival will
be analysed using Kaplan–Meier techniques, and the treatment arms
will be compared by the log-rank test; hazard ratios and 95% con-
fidence intervals will be calculated by Cox proportional hazards
models. The proportions of patients with decline in 6MWD of ≥15%
from baseline will be compared using a Chi-square test with a one-sided
significance level of ɑ=0.05. Change in 6MWD from baseline to 12
months will be compared using a rank ANCOVA model.
Safety will be assessed by AEs, AEs of Grade ≥3, serious AEs,
treatment-related AEs, AEs leading to study drug discontinuation or
interruption, death, exposure to study medication, premature with-
drawal from study and from study medication, laboratory parameters,
ECG and vital signs, and summarised by treatment arm. Time to dis-
continuation will be displayed using Kaplan–Meier techniques.
There are no planned interim analyses for efficacy. Safety interim
analyses will be performed regularly by an independent Data
Monitoring Committee.
3. Discussion
This study is designed to assess the treatment of patients with ad-
vanced disease who have evidence suggestive of PH most likely caused
by IPF. PH is a major contributor to morbidity and mortality in patients
with advanced IPF [11,15,16]. A higher mPAP at initial evaluation of
patients with IPF may be an independent predictor of prognosis [40],
and elevated pulmonary vascular resistance (PVR) may be a strong
haemodynamic predictor of early mortality in patients with diffuse fi-
brotic lung disease, including IPF, regardless of the severity of fibrosis
[41].
In a retrospective analysis of consecutive patients with advanced IPF
(patients undergoing pre-transplant RHC), PH was present in 31.6%
(25/79) of cases [15]. In addition, PH was suspected at baseline on
transthoracic ECHO in 17.2% of patients with IPF enrolled in the INS-
IGHTS-IPF registry [42] , while 40% of patients enrolled in the PROOF
registry had elevated sPAP as measured by ECHO [43]. PH in the
context of pulmonary disease was present in 14% of patients with IPF
and mild-to-moderate physiological impairment enrolled in the AR-
TEMIS-IPF study, as defined by baseline mPAP ≥25mm Hg and pul-
monary capillary wedge pressure≤15mm Hg by RHC [44]. Guidelines
suggest a diagnosis of likely PH can be made when sPAP is > 50mm
Hg by ECHO [45].
Table 4
Secondary efficacy and safety objectives and corresponding endpoints.
Secondary efficacy
objective
Secondary efficacy endpoints
To evaluate the efficacy of
adding sildenafil
compared with placebo
to pirfenidone
•Progression-free survival, defined as time to
decline in 6MWD of ≥15% compared with
baseline, respiratory-related, non-elective
hospitalisation or death from any cause
•Proportion of patients with decline in 6MWD of
≥15% from baseline
•Time to respiratory-related, non-elective
hospitalisation
•Time to death from any cause
•Lung transplant
•Time to all-cause, non-elective hospitalisation
•Time to respiratory-related death
•Change from baseline in transthoracic
echocardiography parameters
•Change from baseline in pulmonary function tests
•Change from baseline SpO2, at rest and during the
6MWT
•WHO functional class
•Dyspnoea (assessed by the UCSD-SOBQ)
•Health-related quality of life (assessed by the
SGRQ)
•N-terminal pro-brain natriuretic peptide level
Safety objective Safety endpoints
To evaluate the safety of
adding sildenafil
compared with placebo
to pirfenidone
•Nature, frequency, severity, relationship and
timing of treatment-emergent adverse events
•Changes in vital signs
•Findings on physical examination
•Clinical laboratory test results
•12-lead ECGs
•Study discontinuation or study drug
discontinuation
6MWD 6-minute walk distance; 6MWT 6-minute walk test; ECG electrocardiogram; SGRQ
St George's Respiratory Questionnaire; SpO2 oxyhaemoglobin saturation; UCSD-SOBQ
University of California, San Diego Shortness of Breath Questionnaire;WHOWorld Health
Organization.
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To date, approved therapies used to treat PH have not been effective
at targeting the underlying fibrotic parenchymal changes that occur in
IPF [18–21]. Studies of ET receptor antagonists have specifically tar-
geted fibrosis rather than the complicating PH. Although a few studies
have shown that targeted therapy with PDE-5 inhibitors or prostacyclin
analogues can improve exercise capacity [46], the use of targeted
therapy in patients with PH in the context of significant lung disease is
not supported by evidence derived from randomised controlled trials,
and there is no agent with regulatory approval for this indication.
Similarly, approved antifibrotic therapies for IPF are unlikely to
have a notable effect on the vascular abnormalities observed in patients
with interstitial lung disease, though no studies have addressed this
directly. With the approval of two antifibrotic therapies for IPF, the
future of IPF management is likely to involve add-on, combination and
sequential therapies, including the use of targeted therapies on a
background of an approved drug with established efficacy. Indeed, a
shift from monotherapy to combination therapy has proven efficacious
in other lung diseases, including lung cancer, chronic pulmonary ob-
structive disease, asthma and PAH [47]. Therefore, combination
treatment constitutes a promising approach to treat patients with ad-
vanced IPF and risk of PH.
Sildenafil, a PDE-5 inhibitor that stabilises cGMP, enhances the
vasodilatory effects and platelet anti-aggregatory activity of NO and
inhibits thrombus formation; these pleiotropic properties may render it
attractive as an add-on treatment for IPF [16,32,48]. Additionally, ex
vivo experiments using pulmonary arteries from healthy donors and
patients with IPF or PH associated with IPF revealed a direct relaxant/
anti-contractile and anti-remodelling role for sildenafil [48].
In patients with IPF and secondary PH, the expected benefits of
pirfenidone and sildenafil combination treatment relate to the antici-
pated improvements in pulmonary haemodynamics by sildenafil in
patients with PH in the context of IPF, while the progression of fibrosis
and decline in lung function will be targeted by pirfenidone. It is also
possible that the addition of sildenafil to pirfenidone therapy could
improve ventilation-perfusion matching, and thus gas exchange,
through preferential vasodilatation in well-ventilated areas [48]. A
reduction in PVR by sildenafil would be expected to improve mPAP,
consequently reducing strain on the right ventricle and improving
cardiac output, assuming that left ventricular function and systemic
vascular resistance are not adversely affected. Improved ventilation-
perfusion matching would be expected to improve gas transfer in the
lung and have a beneficial effect on functional exercise capacity, such
as 6MWD. These haemodynamic effects of sildenafil, in combination
with the known antifibrotic effects of pirfenidone on slowing the rate of
lung function decline, might have a benefit on reducing respiratory
decompensation, related hospitalisations and, potentially, mortality.
A concern with the use of vasodilatory drugs is the potential for
worsening of ventilation-perfusion mismatching and, consequently,
hypoxaemia [16]. However, evidence from preclinical studies showed
that sildenafil did not modify the ventilation-perfusion ratio in a bleo-
mycin model of pulmonary fibrosis associated with PH [48]. In a recent
pilot study, sildenafil did not have a significant effect on gas exchange
in patients with severe PH-associated and chronic obstructive pul-
monary disease [49]. In patients with PH secondary to IPF, sildenafil
improved haemodynamics by maintaining short-term ventilation-per-
fusion matching [29]. Importantly, in STEP-IPF, no significant differ-
ences in the incidence of death, acute exacerbations, AEs or serious AEs
were found between patients with IPF receiving sildenafil and those
receiving placebo [32].
In May 2016, a study assessing the efficacy and safety of riociguat in
patients with symptomatic PH associated with idiopathic interstitial
pneumonia (RISE-IIP; NCT02138825) was prematurely terminated
following a recommendation by the Data Monitoring Committee.
Patients receiving riociguat were observed to be at an increased risk for
death and other serious AEs compared with those receiving placebo
[22]. Although riociguat targets the NO pathway, it has a different
mechanism of action to sildenafil, and acts by enhancing cGMP pro-
duction, whereas sildenafil works by preventing cGMP degradation.
Preclinical studies of sildenafil have revealed no deleterious effect on
hypoxia [48]. Both pirfenidone and sildenafil have well-characterized
safety profiles and are associated with AEs of mild-to-moderate severity
without significant clinical consequence [50,51]. A small case-control
study suggested that pirfenidone and sildenafil may be used safely in
combination in patients with advanced IPF [35]. To address concerns
raised following the early termination of RISE-IIP, and to minimize any
potential risk, a safety plan has been established for the present study,
including appropriate eligibility criteria, dose modification and/or
discontinuation guidelines for identified risks and regular monitoring
by the independent Data Monitoring Committee.
The pharmacokinetics of pirfenidone and sildenafil in isolation have
been well characterised. Pirfenidone is primarily metabolised in the
liver by CYP1A2, with some contribution from other CYPs, and ap-
proximately 80% of pirfenidone or its metabolites are eliminated by the
kidney following oral administration [52]. Sildenafil is rapidly ab-
sorbed, with peak plasma concentrations reached within 1 hour of oral
administration, and is cleared primarily by metabolism (CYP3A4
[major route]; CYP2C9 [minor route]), with no parent drug detectable
in urine or faeces. While no drug–drug interactions have been reported,
an interaction between sildenafil and pirfenidone cannot be eliminated
[53,54].
There are a number of distinctive aspects of the present study as
compared with previous studies, including eligibility based on DLCO,
RHC and ECHO, the use of a composite primary outcome measure and
the strengthened assessment of 6MWD using parameters collected
during the 6MWT (Table 5).
While the presence of PH (defined as an mPAP of ≥25mm Hg at
rest on RHC) is associated with an increased risk of mortality for pa-
tients with IPF [12], data suggest that an mPAP of 17mm Hg may be
the best discriminator of mortality [37]. Therefore, an mPAP ≥20mm
Hg has been selected as an inclusion criterion based on RHC. The 2015
ESC/ERS guidelines on the management of PH define intermediate/
high probability PH based on an ECHO TRV of ≥2.9 m/s [17]. There-
fore, in the absence of a previous RHC, patients with an ECHO showing
a peak TRV ≥2.9m/s will be considered eligible for this study as long
as all other criteria are met.
A DLCO of 40% predicted has been selected as an inclusion criteria in
order to provide overlap with previous clinical studies of pirfenidone,
and, importantly, to increase the likelihood of the study including pa-
tients with pulmonary vasculopathy and a risk of PH. Using a DLCO
inclusion criterion to define patients with advanced IPF, combined with
a RHC/ECHO inclusion criterion, increases the probability that PH will
be present in the study population (Table 5).
The composite primary endpoint will consider exercise capacity
(using the 6MWT) as well as respiratory-related non-elective hospita-
lisations and all-cause mortality. This has been expanded from the
primary endpoint of 6MWD used in previous studies of sildenafil. The
composite endpoint has increased robustness, since it considers re-
spiratory-related hospitalisations as well as hard outcomes, such as all-
cause mortality, which is considered the most robust endpoint in
therapeutic clinical trials. In the pivotal studies of pirfenidone (CAPA-
CITY and ASCEND), progression-free survival was defined as time to
death or disease progression (confirmed ≥10% absolute decline in
percent predicted FVC or confirmed ≥50-m decline in 6MWD) [7].
However, the use of a 50-m decline in 6MWD as an endpoint is not
appropriate in patients with advanced disease, such as those who will
be enrolled in the present study, owing to the low baseline observed in
these patients [55].
Finally, by strengthening the definition of the primary endpoint
6MWT assessment using additional parameters collected during the
test, patients experiencing a decline will not need to perform an addi-
tional 6MWT to reconfirm the decline, thereby reducing the need for a
further clinic visit.
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4. Conclusions
In conclusion, this study will investigate the use of sildenafil added
to pirfenidone in patients with advanced IPF and secondary PH, for
whom no effective therapies are currently available. Combination
treatment may address an unmet need in these patients by providing
effective therapies that target PH in addition to the underlying fibrotic
process.
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